NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been assigned an average rating of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $44.30.

NAMS has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. Royal Bank Of Canada lifted their price target on NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. HC Wainwright initiated coverage on shares of NewAmsterdam Pharma in a research note on Monday, October 20th. They set a “buy” rating and a $52.00 price objective for the company. Needham & Company LLC raised their target price on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, Citigroup boosted their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total transaction of $3,874,500.00. Following the completion of the sale, the chief accounting officer owned 15,000 shares of the company’s stock, valued at approximately $387,450. The trade was a 90.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James N. Topper acquired 1,260 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was purchased at an average price of $24.99 per share, for a total transaction of $31,487.40. Following the completion of the acquisition, the director owned 3,027,864 shares in the company, valued at approximately $75,666,321.36. This trade represents a 0.04% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have sold 176,342 shares of company stock valued at $4,533,519. Insiders own 20.84% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quarry LP acquired a new position in NewAmsterdam Pharma during the first quarter valued at approximately $25,000. Mather Group LLC. purchased a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at $30,000. Wolverine Asset Management LLC acquired a new position in shares of NewAmsterdam Pharma during the 3rd quarter valued at $69,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in NewAmsterdam Pharma by 18.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock worth $79,000 after purchasing an additional 662 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS opened at $37.71 on Friday. The firm has a market cap of $4.28 billion, a PE ratio of -18.40 and a beta of 0.05. The firm has a 50 day simple moving average of $33.71 and a 200-day simple moving average of $25.66. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $41.47.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The firm had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.